Kemwell Biopharma, a global biopharmaceutical contract development and manufacturing company, has announced that it has expanded its analytical capabilities in India to service an FTE contract for a large multinational pharmaceutical company.
Ninad Deshpanday, President of R&D at Kemwell said, "Kemwell has invested in a dedicated facility to meet the needs of this very important customer. The scope of the project includes method transfer, stability sample analyses and analytical method validation for various projects for the customer. We are actively looking to invest in and grow our development business."
Kemwell will employ 15 scientists dedicated for this project. Today, Kemwell's R&D division employs more than 100 scientists and provides services ranging from formulation development, analytical development and validation to clinical trial manufacturing. The team has experience working on early stage development programs for NCE's, ANDA's, 505 (b) (2) and product life cycle management projects. The new analytical lab is equipped with 10 HPLC's, one UPLC and nine dissolution apparatus and other major analytical instruments.
Kemwell Biopharma is headquartered in Bangalore, and manufactures and develops products for companies, including AstraZeneca, GlaxoSmithKline, Bayer, Novartis, Merck Group, Boehringer Ingelheim and Pfizer. The company employs more than 1000 employees worldwide and has seven production facilities, five in India and two in Sweden. Kemwell is an approved pharmaceutical manufacturer in over 80 countries including the American, European, Japanese and Indian markets.